Asitri Dashboard

Search Clinical Trials

The U.S. National Library of Medicine provides a database of clinical trials worldwide. Use the fields below to search the database. Expand your results and select terms or phrases and right-click to search using Google, MalaCards, MedlinePlus, PubMed, or Wikipedia.

Saved Searches

Choose Search
Basic Search
Targeted Search

Clinical Trials Search Results

Query: "AREA[SponsorSearch](Theravance Biopharma)"
Count: 66
Selected: 0
NCT IDTitle
NCT04688632Thorough QT Study to Evaluate Ampreloxetine in Healthy Subjects
NCT04681079Comparison of Viral Particle Dispersion Following Administration of an MDI or Nebulizer in Subjects With COVID-19
NCT04589260TD-1058 First-In-Human Study in Healthy Subjects and Subjects With Idiopathic Pulmonary Fibrosis
NCT04587713Single Dose Bioavailability and Ethnobridging PK Study in Healthy Subjects
NCT04402866TD-0903 for ALI Associated With COVID-19
NCT04350736First in Human SAD and MAD Study of Inhaled TD-0903, a Potential Treatment for ALI Associated With COVID-19
NCT04200573Effect of Hepatic Impairment on the Pharmacokinetics of a Single Dose of TD-9855
NCT04150341Effect of Inhaled TD-8236 on Allergen-induced Asthmatic Response
NCT04095793Phase 3 Open-Label Extension Study of TD-9855 for Treating Symptomatic nOH in Subjects With Primary Autonomic Failure
NCT04044339Single and Multiple Ascending Dose, First-in- Human Study in Healthy Subjects
NCT03920254TD-1473 Long-Term Safety (LTS) Ulcerative Colitis (UC) Study
NCT03829657Phase 3 Clinical Effect Durability of TD-9855 for Treating Symptomatic nOH in Subjects With Primary Autonomic Failure
NCT03758443Efficacy & Safety of TD-1473 in Ulcerative Colitis
NCT03750565Multiple Dose Ethnobridging PK Study in Healthy Subjects
NCT03750552Clinical Effect of Ampreloxetine (TD-9855) for Treating Symptomatic nOH in Subjects With Primary Autonomic Failure
NCT03652038Single and Multiple Ascending Dose Study of TD-8236 by Inhalation
NCT03635112Efficacy and Safety of TD-1473 in Crohn's Disease
NCT03555617Food-effect, Drug-Drug Interaction (DDI), and Formulation Bridging Study
NCT03432793Drug-Drug Interaction (DDI) Study for TD-9855
NCT03408470TD-1473 Absorption, Distribution, Metabolism and Excretion (ADME) Study in Healthy Male Subjects
NCT03103412TD-3504 SAD in Healthy Subjects and Subjects With Ulcerative Colitis (UC)
NCT02954263Multiple Ascending Dose Study of TD-1439 in Healthy Adult and Elderly Subjects
NCT02903095Single Ascending Dose Study of TD-1439 in Healthy Subjects
NCT02818686TD-1473 for Active Ulcerative Colitis (UC)
NCT02709928Multiple Ascending Dose Study of TD-0714 in Healthy and Elderly Subjects
NCT02705755TD-9855 Phase 2 in Neurogenic Orthostatic Hypotension (nOH)
NCT02657122SAD and MAD Study to Evaluate Safety, Tolerability, and Pharmacokinetics (PK) of TD-1473 in Healthy Subjects
NCT02639078Single Ascending Dose Study of TD-0714 in Healthy Subjects
NCT02267525The Diabetic and Idiopathic Gastroparesis Efficacy, Safety, and Tolerability (DIGEST) Study
NCT02116543TD-6450 MAD Study in HCV Infected Subjects
NCT02022306TD-6450 SAD and MAD in Healthy Subjects
NCT01949103TD-1607 MAD Study in Healthy Subjects
NCT01924143TD-9855 Mass Balance Study
NCT01791049TD-1607 SAD Study in Healthy Subjects
NCT01718938Phase 2 Study of Velusetrag in Diabetic or Idiopathic Gastroparesis
NCT01702194TD-1211 IV/Oral Mass Balance Study
NCT01693692Phase 2 Study of TD-9855 to Treat Fibromyalgia
NCT01655771TD-1211 Single-Dose Study in Elderly and Young Healthy Subjects
NCT01644240A Phase 1, Multiple Intravenous Dose Study to Examine Safety, Tolerability, and PK of Intravenous TD-8954, a 5-HT4 Receptor Agonist, in Healthy Subjects
NCT01568411A Fixed-Sequence, Two-Period, Open-Label Drug-Drug Interaction Study to Assess the Effect of an Inhibitor of Cytochrome P450 Isoenzyme 3A4 and Permeability Glycoprotein 1 on the Pharmacokinetics of TD-1211
NCT01467726Safety, Pharmacokinetics and Pharmacodynamics of Velusetrag in Healthy Elderly Subjects
NCT01459926A Double-Blind, Randomized, Placebo-Controlled, Parallel-Group Study to Assess the Safety and Efficacy of TD-1211 in Subjects With Opioid-Induced Constipation
NCT01458340A Study of TD-9855 in Adults With Attention-Deficit/Hyperactivity Disorder (ADHD)
NCT01401985A Study of TD-1211 in Subjects With Opioid-Induced Constipation (OIC)
NCT01333540A Study to Assess the Safety, Tolerability and Clinical Activity of TD-1211 in Patients With Opioid-Induced Constipation
NCT01040637A Multiple Dose Study of TD-1211 in Healthy Volunteers and Patients With Opioid-Induced Constipation
NCT00442832TD-1792 in Gram-positive Complicated Skin and Skin Structure Infection
NCT00391820Evaluate the Safety and Efficacy of a 5-HT4 Agonist in Chronic Constipation (ACCORD Trial)
NCT03573817A 42-day Parallel Group Safety Study of Revefenacin and Formoterol, Administered in Sequence and as a Combination, in Participants With COPD
NCT03095456Revefenacin Peak Inspiratory Flow Rate (PIFR) Study in COPD